Canadian Institute of Advanced Research (CIAR) recently announced the formation of new program that will analyze genetic networks as clues to human disease.
Data management company Unleashed Informatics recently introduced its Unleashed Global Services arm to complement its bioinformatics software and hardware offerings.
Dana Farber Cancer Institute (DFCI), 454 Life Sciences and other research centers performed detailed sequencing experiments to identify subtle but significant cancer-associated mutations.
Metabolex announced a strategic agreement with Ortho-McNeil to collaborate on the development and commercialization of compounds targeting metabolic disorders.
Because of their pivotal role in so many cell growth functions, microtubules are popular targets for anti-cancer drugs. Unfortunately, drug resistance and toxicity can be significant problems.